1. Home
  2. NSRX vs LTRN Comparison

NSRX vs LTRN Comparison

Compare NSRX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.18

Market Cap

25.8M

Sector

Health Care

ML Signal

HOLD

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$2.14

Market Cap

22.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSRX
LTRN
Founded
2019
2013
Country
Israel
United States
Employees
7
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.8M
22.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NSRX
LTRN
Price
$3.18
$2.14
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$19.67
N/A
AVG Volume (30 Days)
107.6K
255.1K
Earning Date
03-25-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.65
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.98
$1.11
52 Week High
$9.99
$5.74

Technical Indicators

Market Signals
Indicator
NSRX
LTRN
Relative Strength Index (RSI) 53.67 46.80
Support Level $2.16 $1.11
Resistance Level $4.49 $2.41
Average True Range (ATR) 0.50 0.29
MACD 0.05 -0.03
Stochastic Oscillator 40.97 19.77

Price Performance

Historical Comparison
NSRX
LTRN

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Share on Social Networks: